Latest Safety News

Tryptamine Therapeutics has secured ethics approval to begin a pioneering clinical trial of TRP-8803, an IV-infused psilocin treatment, targeting adult patients with Binge Eating Disorder. The trial aims to evaluate safety and efficacy, with initial results expected by the end of 2025.

Vection Technologies has secured a $2.6 million contract to co-develop SAFE-XR, an AI-powered safety compliance platform using augmented reality and wearable tech for industrial inspections in Italy.

X2M Connect has secured a $3 million deal to supply 100,000 IoT-connected personal safety devices for Seoul’s 2025 Smart City initiative, with potential to scale to one million units.

PYC Therapeutics has gained FDA alignment on the design of its pivotal Phase 2/3 trial for VP-001, a promising treatment for the rare childhood blindness RP11. The regulator accepted the trial’s sham control arm and primary endpoints, setting the stage for a critical next step toward drug approval.

Immutep reports promising Phase I results for IMP761, a novel LAG-3 agonist antibody demonstrating significant T cell inhibition and a clean safety profile, advancing hopes for new autoimmune disease treatments.

EV Resources has appointed Miguel Barahona as President of its Mexican subsidiary to lead the restart of the Los Lirios open pit antimony mine, signalling a strategic push to advance its operations in Oaxaca.

Zoono Group Limited is raising nearly $1.8 million through a non-renounceable rights issue to fund its supermarket shelf-life extension project in Asia and reduce related party debt.

Provaris Energy has signed a pivotal Memorandum of Understanding with global shipping giant K LINE to advance the commercialisation of compressed hydrogen carriers, targeting Europe's growing hydrogen import demand by 2030.

NeuroScientific Biopharmaceuticals reveals compelling clinical evidence supporting its StemSmart MSC therapy for severe steroid-refractory graft versus host disease, advancing its strategic acquisition plans.

Race Oncology has successfully dosed the first patient with its RC220 and doxorubicin combination in a Phase 1 trial for advanced solid tumours, reporting no dose-limiting side effects. This milestone marks a key step in evaluating the safety and potential cardioprotective benefits of the novel therapy.

Amplia Therapeutics has announced a second confirmed complete response in its ACCENT trial for advanced pancreatic cancer, a notably rare achievement in this challenging disease.

Aurelia Metals has unveiled a robust growth strategy targeting around 40,000 tonnes of copper equivalent production by fiscal 2028, backed by a strong balance sheet and multiple development projects. The company is advancing key operations in the Cobar region while emphasizing operational discipline and sustainability.